Bizengri Approved to Treat Some Lung, Pancreatic Cancers
Mar 26, 2025 · FDA has approved zenocutuzumab (Bizengri) to treat lung and pancreatic cancers with a rare genetic alteration called an NRG1 fusion.
Phase 2 eNRGy Trial: Zenocutuzumab Shows ‘Early and Durable …
Dec 11, 2025 · Zenocutuzumab showed “clinically meaningful early and durable responses” in patients with NRG1 -positive non–small cell lung cancer (NSCLC), with a longer duration of …
FDA grants accelerated approval to zenocutuzumab-zbco
On December 4, 2024, the FDA granted accelerated approval to zenocutuzumab-zbco for non-small cell lung cancer and pancreatic adenocarcinoma.
FDA Approves Zenocutuzumab for Pancreatic and Lung Cancers …
Feb 6, 2025 · The FDA has granted accelerated approval to zenocutuzumab for treating patients with advanced pancreatic cancer or non-small cell lung cancer with an alteration called an …
Zenocutuzumab: Uses in Cancer, Side Effects, Dosages, …
Mar 3, 2025 · What Cancers Is Zenocutuzumab Approved to Treat? Zenocutuzumab has received FDA approval for the treatment of advanced or metastatic non-small cell lung cancer (NSCLC) …
FDA Approves Zenocutuzumab-zbco to Treat Non-small Cell Lung Cancer …
Feb 20, 2025 · On 4 December 2024, FDA granted accelerated approval to zenocutuzumab-zbco (Bizengri®) for the treatment of adults with advanced, unresectable, or metastatic non-small …
Accelerated approval for drug targeting NRG1 - Lung Cancer …
Jan 14, 2025 · The good news The U.S. Food and Drug Administration (FDA) has granted accelerated approval to zenocutuzumab-zbco for the treatment of adult patients with …
Zenocutuzumab Yields Durable Responses in Treatment-Naive …
Dec 8, 2025 · Zenocutuzumab-zbco (Bizengri) showed potential in patients with treatment-naive non–small cell lung cancer (NSCLC) harboring an NRG1 gene fusion in results from a post …
Lung Cancer Novel Agents in Metastatic NSCLC
Dec 13, 2025 · Lung cancer affects more than 200,000 people in the United States annually; non–small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases. …
First Systemic Therapy Approved for Lung and Pancreatic Cancers …
The FDA approved the targeted therapy zenocutuzumab-zbco for certain patients with lung or pancreatic cancer. The U.S. Food and Drug Administration (FDA) has granted accelerated …